Lead Sponsor

Amgen

Age

12 - 100 years

Sex

ALL

Healthy Volunteers

No

•Age ≥ 12 at Day 1.
•Diagnosis of AD according to American Academy of Dermatology (AAD) Consensus Criteria (2014) that has been present for at least 12 months.
•History of inadequate response to Topical Corticosteroids (TCS) of medium to higher potency (with or without topical calcineurin inhibitors \[TCI\]).
•Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) score ≥ 3 at screening and pre-randomization.
•Eczema Area and Severity Index (EASI) score ≥ 16 at initial at screening and pre-randomization.
•≥ 10% body surface area (BSA) of AD involvement at screening and pre-randomization.

•Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to day 1 pre-randomization.
•Treatment with any of the following medications or therapies within 5 half-lives prior to day 1 pre-randomization:
•1. Systemic corticosteroids
•2. Non-biologic, non-targeted systemic immunosuppressants
•3. Oral or Topical Janus kinase inhibitors
•Treatment with any of the following medications or therapies within 1 week before day 1 pre-randomization:
•1. Topical phosphodiesterase 4 (PDE4) inhibitors
•2. Other topical immunosuppressive agents (not including TCS/TCI)
•3. Combination topical agents containing any of the above components